A Non-interventional Observational Post Authorization Study to Evaluate Safety and Efficacy in Patients Receiving Azacitidine in Daily Clinical Practice in the Netherlands (OCEAN)
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Myelodysplastic Syndromes
- Sponsor
- Celgene
- Enrollment
- 209
- Primary Endpoint
- Adverse Events (AEs)
- Status
- Completed
- Last Updated
- 6 years ago
Overview
Brief Summary
The study design is a prospective, non-interventional, observational single arm study.
A minimum of 150 patients will be recruited from approximately 30 haematology/oncology sites in the Netherlands. In all cases, the decision to treat the patient with azacitidine was already made prior to the decision to enter the subject into the study.
Recruitment will continue until end of June 2015, provided a minimum of 150 patients have been included in the study. When this date is reached, all patients on azacitidine will continue to be followed until the last patient enrolled has been followed for 12 months.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patients over 18 years of age who understand and voluntarily sign an informed consent form.
- •Patients who are treated with azacitidine in accordance with registered indication and clinical practice.
Exclusion Criteria
- •Refusal to participate in the study.
- •Participation in an interventional clinical study.
- •Patients previously treated with azacitidine except when given as induction therapy for a maximum of three courses.
- •Women who are pregnant or breast-feeding.
- •Hypersensitivity to the active substance or to any of the excipients.
- •Advanced malignant hepatic tumors.
Outcomes
Primary Outcomes
Adverse Events (AEs)
Time Frame: Up to approximately 4 years
Adverse events will be classified using the Medical Drug Regulatory Activities (MedDRA) classification system. The severity of the toxicities will be graded according to the NCI CTCAE VERSION 4.03 whenever possible
Secondary Outcomes
- Percentage of patients with a Hematologic Improvement Using International Working Group (IWG Criteria for Hematologic Improvement Cheson 2000) Criteria for Myelodysplastic Syndrome (MDS) and Assessed by the investigator in daily clinical practice(Up to approximately 4 years)
- Fact-Anemia Quality of life questionnaire(Up to approximately 4 years)
- Percentage of patients with a Haematological Response in daily clinical practice using the International Work Group Criteria in Myelodysplastic Syndrome Assessed by the Investigator(Up to approximately 4 years)
- Time to treatment Failure daily clinical practice(Up to approximately 4 years)
- Overall Survival in daily clinical practice(Up to approximately 4 years)